Navigation Links
Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
Date:11/5/2009

nine months of 2009 were $10.6 million and $36.5 million, respectively, compared with $10.4 million and $32.3 million in 2008.

Net loss for the third quarter and nine months ended Sept. 30, 2009, was $6.2 million, or $0.33 per diluted common share, and $23.9 million, or $1.31 per diluted common share, respectively. This is compared with a net loss of $6.6 million, or $0.37 per diluted common share, and $19.2 million, or $1.07 per diluted common share, in 2008.

Trubion had $61.7 million in cash, cash equivalents and investments as of Sept. 30, 2009, compared with $52.9 million as of Dec. 31, 2008.

"Over the past nine months, we have continued to advance our clinical programs, including TRU-015 for rheumatoid arthritis, TRU-016 for chronic lymphocytic leukemia and SBI-087 for rheumatoid arthritis and systemic lupus erythematosus," said Peter Thompson, M.D., FACP, president, chief executive officer and chairman of Trubion. "The data we've collected from each study to-date suggests that these product candidates may provide differentiated, best-in-class treatments for patients with autoimmune and inflammatory diseases, or cancer. In addition, our Facet agreement has significantly extended our runway, and we continue to meter our expenses to reduce our previously anticipated cash burn rate."

Recent milestones

  • On Aug. 27, 2009, Trubion entered into an agreement with Facet for the worldwide development and commercialization of TRU-016, a CD37-directed product candidate in phase 1 clinical development for the treatment of chronic lymphocytic leukemia (CLL). Trubion received an upfront payment of $20 million and may receive up to $176.5 million in additional contingent payments upon the achievement of certain development, regulatory and sales milestones. In addition, Facet purchased 2,243,649 shares of Trubion common stock for an aggregate purchase of $10 million, or $4.46 per share.
  • Trubion present
    '/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Announces Upcoming Presentation at 8th Annual BIO Investor Forum
2. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
3. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
6. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
7. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
8. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
9. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
10. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
11. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s Hospital ... from 3D printing of their anatomy before undergoing ... cerebrovascular malformations (abnormalities in the brain,s blood vessels) ... online today in the Journal of Neurosurgery: ... 3D printing and synthetic resins to create custom, ...
(Date:7/31/2015)... Scientific, Inc. (Nasdaq: SMLR ), a company that ... physician groups, today reported financial results for the second ... the second quarter of 2015, Semler reported continued progress ... over quarter revenue growth of 8%, and quarter over ... of 18%," said Doug Murphy-Chutorian, M.D., chief executive officer ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... 27 ChemoCentryx, Inc., today announced that ... PROTECT-1 Study (the Prospective Randomized Oral Therapy ... (CCX282-B) in patients with moderate-to-severe Crohn,s disease. ... antagonist showed clinical efficacy in a 12-week ...
... NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... specializing in the development, manufacturing, and marketing of branded ... it will report its unaudited financial results for the ... 11, 2010, before the market opens in the United ...
Cached Medicine Technology:ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 2ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 3ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 4ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting 5Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010 2
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... Ticket ... which is currently going on in Chicago at Grant Park. The festival will ... corner of North America to Chicago for the annual Lollapalooza. This unique and ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to ... Downtown Memphis on October 3, 2015. The Ride to Fight On is a cycling ... between Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin ... re-branded their social media profiles to better connect with the public. The agency ... find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to the article published July 27 ... Pasadena courthouse was contained and extinguished by the city’s fire department before it caused major ... at the time of the fire, and it was a fire alarm system that tipped ...
(Date:7/31/2015)... ... 2015 , ... Cosmetic Town has proven itself as the ... surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. ... fillers. , Staying up to date with the latest cosmetic trends has ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2
... visits flood affected states of Tabasco and Chiapas, ... recording artist Clay Aiken today wrapped up the first,leg ... southeast Mexico by,participating in a gift exchange and "sing ... camp erected for flood victims., (Photo: http://www.newscom.com/cgi-bin/prnh/20071225/AQTU002 ...
... Kaiser Permanente is,providing 40 Atlanta-area nonprofit organizations with ... over $1.4 million in grant funds to support,local ... to,$250,000 and focus on increasing access to health ... nursing and pharmacy,scholarships; and other community health programs., ...
... /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ), ... products in the People,s Republic of China, announced ... listing of its common stock on,the NASDAQ Global ... Capital,Market to the NASDAQ Global Market has been ...
... media and PPC ads ... pointed to a landing ... of Key Technology, has hired Denver-based interactive marketing agency,90octane to ... (PPC) advertising will send prospects to a landing,page featuring the ...
... veterans shows that those with injuries to certain parts ... stress disorder (PTSD). The findings, from the National ... Center, suggest that drugs or pacemaker-like devices aimed at ... treatments for PTSD. , PTSD involves the persistent reliving ...
... ... Extension, TUCSON, Ariz., Dec. 21 ImaRx Therapeutics,Inc. ... submitted a lot release,request to the Food and Drug ... urokinase drug product. Urokinase, ImaRx,s first,commercially available FDA-approved product, ...
Cached Medicine News:Health News:Clay Aiken & Family Celebrate Christmas With Survivors of Mexico's Floods 2Health News:Kaiser Permanente Provides $1.4 Million in Holiday Gifts to 40 Metro Atlanta Nonprofits 2Health News:Kaiser Permanente Provides $1.4 Million in Holiday Gifts to 40 Metro Atlanta Nonprofits 3Health News:Chindex International, Inc. Announces Transfer to NASDAQ Global Market 2Health News:Chindex International, Inc. Announces Transfer to NASDAQ Global Market 3Health News:90octane Selected as Interactive Marketing Agency for Symetix Lead Generation Program 2Health News:Study suggests some brain injuries reduce the likelihood of post-traumatic stress disorder 2Health News:Study suggests some brain injuries reduce the likelihood of post-traumatic stress disorder 3Health News:ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating 2Health News:ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating 3
2 mm wide tip with 1 mm by 4 mm eye. Curved shaft and ring handle with polished finish....
1 mm x 6 mm oval hole....
Coaptation forceps. Insulated....
Jewelers forceps. Insulated....
Medicine Products: